Analytical Data
-
Gene name
PAX9
- Application
-
Alternative Names
PAX9;Paired box Protein Pax-9
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P55771
-
Expression Region
1-341aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSMEPAFGE VNQLGGVFVN GRPLPNAIRL RIVELAQLGI RPCDISRQLR VSHGCVSKIL ARYNETGSIL PGAIGGSKPR VTTPTVVKHI RTYKQRDPGI FAWEIRDRLL ADGVCDKYNV PSVSSISRIL RNKIGNLAQQ GHYDSYKQHQ PTPQPALPYN HIYSYPSPIT AAAAKVPTPP GVPAIPGSVA MPRTWPSSHS VTDILGIRSI TDQVSDSSPY HSPKVEEWSS LGRNNFPAAA PHAVNGLEKG ALEQEAKYGQ APNGLPAVGS FVSASSMAPY PTPAQVSPYM TYSAAPSGYV AGHGWQHAGG TSLSPHNCDI PASLAFKGMQ AAREGSHSVT ASAL
-
Molecular Weight
39 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PAX9 is a transcription factor that plays a critical role in various developmental processes, particularly in the formation of teeth and certain structures within the craniofacial region. Research has shown that mutations in the PAX9 gene are associated with congenital dental anomalies, making it a significant target for investigating the molecular mechanisms underlying tooth development and related disorders. The production of recombinant PAX9 protein allows scientists to study its functional properties in detail, facilitating a deeper understanding of its role in gene regulation and developmental pathways. By expressing and purifying PAX9 in a laboratory setting, researchers can perform biochemical assays to analyze its interactions with other proteins and DNA, assess its transcriptional activity, and explore the impact of specific mutations on its functionality. This knowledge not only contributes to our understanding of normal biological processes but also has potential implications for developing therapeutic strategies for dental and craniofacial deformities. Additionally, the insights gained from studying PAX9 can further illuminate the broader field of developmental biology and its genetic underpinnings, paving the way for future studies on gene therapy and regenerative medicine. As such, the research on PAX9 recombinant protein is essential for advancing our understanding of genetic regulation in development and the clinical implications of associated pathologies. Through ongoing studies, the characterization of PAX9 will continue to shed light on the intricate network of genetic interactions that govern embryonic development and offer prospects for potential clinical applications in addressing genetic disorders related to dental and craniofacial anomalies.
